Healthcare and life-sciences organizations face a concentrated version of every AI governance challenge: sensitive health data, decisions that can affect patient safety, established quality and validation regimes, and a fast-growing population of generative AI tools in clinical documentation, research and operations.
Priority use cases
| Use case | Why it needs governance | Likely tier |
|---|---|---|
| Clinical documentation and ambient scribing | Health data in prompts; accuracy of clinical records; clinician over-reliance | High |
| Clinical decision support and triage | Potential patient-safety impact; may fall within medical-device rules depending on intended purpose | High or Prohibited-review pending regulatory review |
| Pharmacovigilance case intake and literature screening | Regulated process; missed signals; validation expectations | High |
| Clinical trial operations (site selection, patient matching) | Fairness and representativeness; special-category data | Medium to High |
| Medical information and patient-facing assistants | Transparency to patients; harmful or off-label content | High |
| Internal productivity (summaries, drafting, coding assistants) | Data leakage; shadow AI | Low to Medium |
Regulatory context, carefully stated
- Medical-device software rules. In several jurisdictions, software — including AI — intended for diagnosis, prevention, monitoring or treatment can be regulated as a medical device (for example under the EU Medical Device Regulation or by the US FDA). Qualification depends on intended purpose. AI that is a safety component of, or is itself, a product covered by EU harmonization legislation may also be high-risk under the EU AI Act.
- Health data protection. Health data is special-category data under the GDPR and protected health information under HIPAA in the US; other jurisdictions have equivalents.
- Quality and validation. GxP environments expect computerized systems to be validated and changes controlled — AI components, prompts and models included.
VERITRAIL does not determine how these regimes apply. It ensures the facts that drive those determinations are recorded and that systems are routed to the right reviewers.
VERITRAIL emphasis
- Intended purpose discipline (EI-04). Precise intended-purpose statements, foreseeable misuse and out-of-scope uses — the foundation for both device qualification analysis and EU AI Act classification.
- Data and privacy (EI-06, IS-03, IS-04). Lineage of health data, privacy impact assessment, and redaction before any external model call.
- Human oversight (IS-09). Clinician review designs that account for automation bias, with override and escalation.
- Change control (GL-04, GL-05). Model, prompt and data changes treated as validated-system changes with reassessment triggers.
- Vendor AI (GL-11, EI-08). Ambient scribing and clinical AI vendors assessed for data use, model change notice and incident notification.
VERITRAIL controls cited
- EI-04 Intended purpose and context of useNIST AI RMF: MAP 1.1, MAP 1.2, MAP 3.4ISO/IEC 42001: A.6.2.2, A.9.4EU AI Act: Art. 11, Art. 13
- IS-03 Privacy assessment and data minimisationNIST AI RMF: MEASURE 2.10, MAP 1.1ISO/IEC 42001: A.7.4, A.5.4EU AI Act: Art. 10
- IS-04 Sensitive data redaction and maskingNIST AI RMF: MEASURE 2.10ISO/IEC 42001: A.7.4, A.6.2.6EU AI Act: Art. 10
- IS-09 Human oversight designNIST AI RMF: GOVERN 3.2, MAP 3.5ISO/IEC 42001: A.9.2, A.6.2.6EU AI Act: Art. 14, Art. 26
- GL-04 Change management and reassessment triggersNIST AI RMF: GOVERN 1.4, MANAGE 2.4ISO/IEC 42001: 6.3, A.6.2.6EU AI Act: Art. 43
- GL-11 Vendor AI due diligence and contract controlsNIST AI RMF: GOVERN 6.1, MAP 4.1ISO/IEC 42001: A.10.3, A.10.4EU AI Act: Art. 25
Framework mappings are indicative VERITRAIL interpretations (Control Library v1.0.0); they are not legal advice and do not establish conformity or compliance.
Typical first 90 days
| Days | Focus | Outputs |
|---|---|---|
| 1–30 | Inventory clinical, research and operational AI including vendor tools; screen for potential device or high-risk relevance; stand up governance forum with clinical safety and quality representation | Inventory with owners; regulatory review list; forum charter |
| 31–60 | Pre-deployment assessments for High-tier systems; privacy assessments; redaction for generative AI handling health data; change triggers aligned with validation SOPs | Assessments; redaction configuration; updated change procedure |
| 61–90 | Oversight designs for clinical-facing AI; runtime guardrails for patient-facing assistants; evidence pack for the highest-risk system | Oversight designs; draft Shield policies; first evidence pack |